The ALK receptor in sympathetic neuron development and neuroblastoma

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cell and Tissue Research

• Publication date

  2018-01-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00441-017-2784-8PMID 29374774
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma

  2017cited by this paper
• The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.

  2017cited by this paper
• Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer

  2017cited by this paper
• MYCN induces neuroblastoma in primary neural crest cells

  2017cited by this paper
• Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models

  2017cited by this paper
• Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

  2017cited by this paper
• Multipotent peripheral glial cells generate neuroendocrine cells of the adrenal medulla

  2017cited by this paper
• Phosphoproteomics reveals ALK promote cell progress via RAS/JNK pathway in neuroblastoma

  2016cited by this paper
• The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

  2016cited by this paper
• Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma.

  2016cited by this paper
• Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma

  2016cited by this paper
• Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling

  2016cited by this paper
• Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK

  2015cited by this paper
• Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

  2015cited by this paper
• ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT

  2015cited by this paper
• FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase

  2015cited by this paper
• Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism of ALK activation in neuroblastoma tumors

  2015cited by this paper
• Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma

  2015cited by this paper
• Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis

  2015cited by this paper
• Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions

  2015influential reference
• Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism

  2015cited by this paper
• Discovery of (10R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2H-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]Benzoxadiazacyclotetradecine-3-Carbonitrile (Pf-06463922), a Macrocyclic Inhibitor of Alk/Ros1 with Pre-Clinical Brain Exposure and Broad Spectrum Potency Against Alk-Resistant

  2014cited by this paper
• Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma

  2014cited by this paper
• Emergence of new ALK mutations at relapse of neuroblastoma.

  2014cited by this paper
• The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

  2014cited by this paper
• The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma

  2014cited by this paper
• Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells

  2014cited by this paper
• Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos

  2014cited by this paper
• Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma

  2014cited by this paper
• A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non–Small Cell Lung Cancer

  2014cited by this paper
• Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome

  2014cited by this paper
• Hyperactivation of Alk induces neonatal lethality in knock-in AlkF1178L mice

  2014cited by this paper
• ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

  2014cited by this paper
• Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells

  2013cited by this paper
• Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma.

  2013cited by this paper
• Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2

  2013cited by this paper
• MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells

  2013influential reference
• Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

  2013cited by this paper
• Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

  2013cited by this paper
• Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells

  2012influential reference
• Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma

  2012cited by this paper
• Anaplastic lymphoma kinase and leukocyte tyrosine kinase: functions and genetic interactions in learning, memory and adult neurogenesis.

  2012influential reference
• LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression

  2012cited by this paper
• Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma

  2012cited by this paper
• The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

  2012cited by this paper
• Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma

  2012cited by this paper
• Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.

  2012cited by this paper
• Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice

  2012cited by this paper
• Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action

  2011cited by this paper
• Frizzled3 Is Required for Neurogenesis and Target Innervation during Sympathetic Nervous System Development

  2011cited by this paper
• Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.

  2011cited by this paper
• Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma

  2011cited by this paper
• The neuroblastoma ALK(I1250T) mutation is a kinase- dead RTK in vitro and in vivo

  2011cited by this paper
• Germline gain‐of‐function mutations of ALK disrupt central nervous system development

  2011cited by this paper
• Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.

  2011cited by this paper
• The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking

  2011influential reference
• Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels

  2011cited by this paper
• The neuroblastoma ALK(I1250T) mutation is a kinase-dead RTK in vitro and in vivo.

  2011cited by this paper
• An Evolutionary Conserved Role for Anaplastic Lymphoma Kinase in Behavioral Responses to Ethanol

  2011cited by this paper
• Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition

  2011influential reference
• CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

  2011cited by this paper
• Transcriptional control of differentiation and neurogenesis in autonomic ganglia

  2011cited by this paper
• EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

  2010cited by this paper
• Sequential requirement of Sox4 and Sox11 during development of the sympathetic nervous system

  2010cited by this paper
• An Orally Available Small-Molecule Inhibitor of c-Met,PF-2341066,Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

  2010cited by this paper
• The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• ALK (Anaplastic Lymphoma Kinase) expression in DRG neurons and its involvement in neuron–Schwann cells interaction

  2009cited by this paper
• BMP signaling regulates sympathetic nervous system development through Smad4-dependent and -independent pathways

  2009cited by this paper
• Behavioral and Neurochemical Alterations in Mice Deficient in Anaplastic Lymphoma Kinase Suggest Therapeutic Potential for Psychiatric Indications

  2008cited by this paper
• Activating mutations in ALK provide a therapeutic target in neuroblastoma

  2008cited by this paper
• Identification of ALK as a major familial neuroblastoma predisposition gene

  2008cited by this paper
• Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

  2008influential reference
• Oncogenic mutations of ALK kinase in neuroblastoma

  2008cited by this paper
• An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

  2007cited by this paper
• Establishment and controlled differentiation of neural crest stem cell lines using conditional transgenesis.

  2007cited by this paper
• In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)?

  2007cited by this paper
• Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation.

  2007cited by this paper
• Anaplastic lymphoma kinase is dynamically expressed on subsets of motor neurons and in the peripheral nervous system

  2006cited by this paper
• Characterization of the expression of the ALK receptor tyrosine kinase in mice.

  2006cited by this paper
• Delays in neuronal differentiation in Mash1/Ascl1 mutants.

  2006cited by this paper
• Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells

  2005cited by this paper
• Activation and Inhibition of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase by Monoclonal Antibodies and Absence of Agonist Activity of Pleiotrophin*

  2005cited by this paper
• Imperfect protection: NEPA at 35 years.

  2004cited by this paper
• Essential role of Gata transcription factors in sympathetic neuron development

  2004cited by this paper
• ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth

  2004influential reference
• Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines

  2002cited by this paper
• A Ligand-inducible Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase Chimera Promotes Mitogenesis and Transforming Properties in 3T3 Cells*

  2002cited by this paper
• Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types*

  2002cited by this paper
• Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin*

  2001cited by this paper
• Activation of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase Induces Neuronal Differentiation through the Mitogen-activated Protein Kinase Pathway*

  2001cited by this paper
• The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives

  1999cited by this paper
• Immortalization and controlled in vitro differentiation of murine multipotent neural crest stem cells.

  1997cited by this paper
• Targeted expression of MYCN causes neuroblastoma in transgenic mice

  1997cited by this paper
• ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

  1997cited by this paper
• Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

  1997cited by this paper
• Evidence for an important role of IGF-I and IGF-II for the early development of chick sympathetic neurons.

  1995cited by this paper
• c-ros: the vertebrate homolog of the sevenless tyrosine kinase receptor is tightly regulated during organogenesis in mouse embryonic development.

  1992cited by this paper

• Flocoumafen exposure induces skeletal developmental toxicity and neurotoxicity in zebrafish (Danio rerio).

  2026cites this paper
• NEK7 phosphorylation of cortactin modulates the migratory capacity of cells expressing EML4-ALK V3

  2025cites this paper
• Therapeutic potential of lorlatinib in ALK-mutated metastatic paraganglioma: insights from clinical case report and literature review.

  2025cites this paper
• Peripheral neuroblastic tumors behaving badly: an update on high-risk morphologic and molecular groupings

  2025cites this paper
• 15 Years Old ALK Gene from Birth to Adolescence; Where to in NBL

  2025cites this paper
• mRNA Expression Level of ALK in Neuroblastoma Is Associated with Histological Subtype, ALK Mutations and ALK Immunohistochemical Protein Expression

  2024cites this paper
• ALK Gene Mutation and ALK Protein Expression in Advanced Neuroblastoma and the Potential Value in Risk Stratification in Fine-Needle Aspiration Biopsy Samples.

  2023cites this paper
• Human iPSC modeling recapitulates in vivo sympathoadrenal development and reveals an aberrant developmental subpopulation in familial neuroblastoma

  2023cites this paper
• Target therapy for high-risk neuroblastoma treatment: integration of regulatory and scientific tools is needed

  2023cites this paper
• Pharmacological profiling identifies divergent chemosensitivities of differentiating and maturing iPSC‐derived human cortical neuron populations

  2023cites this paper
• LTK and ALK promote neuronal polarity and cortical migration by inhibiting IGF1R activity

  2023cites this paper
• LTK and ALK regulate neuronal polarity and cortical migration by modulating IGF1R activity

  2023cites this paper
• Signaling by Receptor Tyrosine Kinases Signaling by Receptor Tyrosine Kinases ↗ Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) ↗

  2022cites this paper
• Signaling by ALK

  2022cites this paper
• Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation

  2022cites this paper
• Acoustically Accelerated Neural Differentiation of Human Embryonic Stem Cells.

  2022cites this paper
• Protein Tyrosine Phosphatases in Neuroblastoma: Emerging Roles as Biomarkers and Therapeutic Targets

  2021cites this paper
• 5′ ALK Amplification in Neuroblastoma: A Case Report

  2021cites this paper
• Prognostic and predictive markers in glioblastoma and ALK overexpression

  2021cites this paper
• Molecular Genetics in Neuroblastoma Prognosis

  2021cites this paper
• The clinical and prognostic role of ALK in glioblastoma.

  2021cites this paper
• Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology

  2021cites this paper
• A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma

  2021cites this paper
• Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma

  2021cites this paper
• Single-cell transcriptomic analysis identifies neocortical 1 developmental differences between human and mouse 2 3

  2020cites this paper
• Neuronal lineages derived from the nerve-associated Schwann cell precursors

  2020cites this paper
• SMAD-oncoprotein interplay: Potential determining factors in targeted therapies.

  2020cites this paper
• Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook

  2020cites this paper
• Single-cell transcriptomic analysis identifies neocortical developmental differences between human and mouse

  2020cites this paper
• Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer

  2020cites this paper
• Collaborative ISL1/GATA3 interaction in controlling neuroblastoma oncogenic pathways overlapping with but distinct from MYCN

  2019cites this paper
• Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells

  2019cites this paper
• Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma

  2019cites this paper
• ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations

  2019cites this paper
• Expression of the Neuroblastoma-Associated ALK-F1174L Activating Mutation During Embryogenesis Impairs the Differentiation of Neural Crest Progenitors in Sympathetic Ganglia

  2019cites this paper
• Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides

  2019cites this paper
• Neuroblastoma Pathogenesis

  2019cites this paper
• Developing new models of childhood malignancies using human induced pluripotent stem cells

  2019cites this paper
• Dual-Specificity Phosphatases in Neuroblastoma Cell Growth and Differentiation

  2019cites this paper
• The sympathetic nervous system: malignancy, disease, and novel functions

  2018influential citation